Granules India (GRANULES) Share Price Falls 2.17%: What Today’s Decline Shows

Granules India Share Price fell to Rs 819.45 on 02 September 2026 at 9:54:33 AM IST, down 2.17% or Rs 18.15 from the previous close of Rs 837.60. The move took the company’s market capitalisation to Rs 20,518.82 crore. The stock, classified as a Large Cap name in the supplied dataset, opened at Rs 837.50 and moved lower toward an intraday low of Rs 818.30.

The available data confirms the decline, but it does not identify a company-specific trigger. That means the session can be assessed more usefully through price behaviour, valuation, profitability and industry benchmarks in Healthcare and Pharmaceuticals & Drugs rather than by attaching an unsupported reason to the move.

At the time captured, the company was trading at a P/E of 31.34 and a P/B of 4.24, while ROE stood at 14.13 and ROCE at 15.74. These figures matter because they show where the stock sits against the wider pharma pack even on a day when the headline is a price decline. Investors watching the counters in this segment may also note that the stock’s RSI was 44.52, the 50-day DMA was 846.22 and the 200-day DMA was 714.86.

Granules India (GRANULES) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 819.45
Previous Close	Rs 837.6
Today's Move	-Rs 18.15 (-2.17%)
Open	Rs 837.5
High	Rs 837.5
Low	Rs 818.3
Turnover	Rs 0.63 crore
Market Capitalisation	Rs 20,518.82 crore
Market Cap Category	Large Cap

Granules India Share Price Today showed weakness from the opening phase itself. The stock opened at Rs 837.50, almost unchanged from the previous close of Rs 837.60, but it did not move above that opening mark during the period covered by the data. The day’s high was also Rs 837.50, while the low slipped to Rs 818.30 before the stock traded at Rs 819.45.

That intraday structure indicates selling pressure after a flat start rather than a late reversal from higher levels. The difference is important because it frames the move as a sustained morning decline. Turnover stood at Rs 0.63 crore, which confirms activity in the counter, though turnover alone cannot explain why the stock moved down.

From a technical reference point, the current price sits below the 50-day DMA of 846.22 but above the 200-day DMA of 714.86. The RSI reading of 44.52 places the stock in a neutral-to-soft zone based on the supplied data, without signalling an extreme condition on its own. Together, these numbers suggest that the session has weakened the near-term picture while the longer-term reference level remains lower than the current traded price.

Granules India (GRANULES) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 20,518.82 crore
P/E Ratio	31.34x
P/B Ratio	4.24x
ROE	14.13%
ROCE	15.74%
EPS	Rs 26.73
Book Value Per Share	Rs 197.72
Dividend Yield	0.21%

Granules India’s fundamentals place it in a middle zone on valuation, with double-digit profitability and a sizeable market value for its industry. The stock trades at 31.34 times earnings and 4.24 times book value. EPS stands at Rs 26.73, book value per share at Rs 197.72 and dividend yield at 0.21%.

ROE of 14.13% and ROCE of 15.74% indicate that the business is generating returns above low-double-digit levels on both equity and capital employed. Those metrics do not, by themselves, explain the one-day price decline, but they help anchor how the company is positioned fundamentally. The market capitalisation of Rs 20,518.82 crore also underlines that this is not a very small pharmaceutical name within the listed universe.

As a result, Granules India Share Price is being read less as a pure momentum story and more as a valuation-and-returns case. When a stock with benchmark-like valuation and above-median profitability slips during the session, the next useful comparison is with the wider industry baseline rather than with speculation around a missing catalyst.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	31.34x
Benchmark Median P/E	31.29x
Benchmark Average P/E	48.12x
Benchmark P/E Range	3.68x to 653.31x
Company P/B Ratio	4.24x
Benchmark Median P/B	2.88x
Benchmark Average P/B	4.35x
Company ROE	14.13%
Benchmark Median ROE	11.79%
Benchmark Average ROE	11.21%
Company ROCE	15.74%
Benchmark Median ROCE	13.63%
Benchmark Average ROCE	13.75%
Company Market Capitalisation	Rs 20,518.82 crore
Benchmark Median Market Cap	Rs 720.34 crore
Benchmark Average Market Cap	Rs 14,208.71 crore

The sector snapshot covers 201 companies in the same industry. On that basis, the company’s P/E of 31.34 is nearly identical to the industry median of 31.29 and below the average of 48.12, based on 169 companies with P/E data. The wider range of 3.68 to 653.31 also shows how broad valuation dispersion is across the industry.

On price-to-book, the company stands at 4.24 versus a median of 2.88 and an average of 4.35 across 200 companies. That puts it above the median but close to the average. On profitability, the picture is somewhat stronger: ROE of 14.13 is above both the median of 11.79 and average of 11.21, while ROCE of 15.74 is above the median of 13.63 and average of 13.75.

Size is another notable point. With a market value of Rs 20,518.82 crore, the company is far above the industry median market cap of Rs 720.34 crore and also above the industry average of Rs 14,208.71 crore. So while today’s price move is negative, it is happening in a relatively large listed pharma company whose valuation is around the industry middle and whose return ratios are somewhat better than the benchmark centre.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,69,309.92	38.29	5.36	14.85	19.11
Divi's Laboratories	DIVISLAB	2,45,425.7	83.18	13.77	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,347.12	86.48	21.02	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,919.92	25.73	4.31	19.69	21.39
Cipla	CIPLA	1,14,392.76	33.99	3.26	11.83	16

Peer data places the company below the biggest frontline pharma names in size, while valuation and profitability sit in a mixed middle band. Compared with Sun Pharmaceutical Industries, it trades at a lower P/E and lower P/B, but also with slightly lower ROE and lower ROCE. Against Divi’s Laboratories and Torrent Pharmaceuticals, valuation is much lower, but those peers also post clearly stronger return ratios.

Versus Zydus Lifesciences, the company trades at a higher P/E and nearly similar P/B, while Zydus shows stronger ROE and ROCE. Compared with Cipla, the P/E is a little lower, the P/B is higher, ROE is stronger and ROCE is just under Cipla’s level. In market capitalisation, the company remains much smaller than all five peers listed in the table, each of which is above Rs 1,14,000 crore.

This comparison does not point to a simple premium-or-discount label across the board. Instead, it shows a stock priced around the industry middle, with profitability better than some peers and weaker than others, and with a much smaller market value than the sector heavyweights. That balanced but not dominant positioning helps explain why a one-day decline still attracts attention.

Why Investors Are Watching Granules India

• Granules India Share Price fell 2.17% to Rs 819.45 from Rs 837.60.
• The stock opened at Rs 837.50, hit a low of Rs 818.30 and remained below the opening level in the captured session data.
• P/E of 31.34 is almost identical to the same-industry median of 31.29.
• ROE of 14.13 and ROCE of 15.74 are above industry medians of 11.79 and 13.63.
• The company’s market cap of Rs 20,518.82 crore is above both the industry median and average.

About Granules India

Granules India is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. In the supplied classification, it is a Large Cap stock. That means the counter sits in a widely tracked part of the market where investors often compare valuation multiples, profitability ratios and market size with other listed drug makers.

Track Granules India Share Price on Univest

Use Granules India (GRANULES) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

Frequently Asked Questions

Why is Granules India Share Price falling today?

Ans.  The stock is down 2.17% at Rs 819.45 versus the previous close of Rs 837.60. The supplied data confirms the decline, but it does not establish a company-specific catalyst behind the move.

What is Granules India Share Price Today?

Ans.  Granules India Share Price Today is Rs 819.45 as of 02 September 2026 at 9:54:33 AM IST. The stock is lower by Rs 18.15 on the day, or 2.17%. The previous close was Rs 837.6.

How did Granules India trade intraday?

Ans.  The stock opened at Rs 837.50, touched an intraday high of Rs 837.50 and fell to a low of Rs 818.30 before trading at Rs 819.45 in the supplied snapshot.

What is the market capitalisation of Granules India?

Ans.  Granules India has a market capitalisation of Rs 20,518.82 crore, placing it in the Large Cap category in the supplied dataset. The company operates in the Healthcare sector. Its P/E ratio is 31.34x.

Is Granules India expensive compared with its industry P/E?

Ans.  It trades at a P/E of 31.34, almost identical to the same-industry median of 31.29 and below the industry average of 48.12. The company trades at a P/E ratio of 31.34x.

How does Granules India compare on profitability?

Ans.  ROE stands at 14.13 and ROCE at 15.74. Both are above the same-industry medians of 11.79 and 13.63. ROE stands at 14.13%. ROCE stands at 15.74%. The relevant peer median ROE is 11.79%.